1,460
Participants
Start Date
April 7, 2014
Primary Completion Date
December 31, 2022
Study Completion Date
December 31, 2025
AZD2014
Target: m-TOR
AZD4547
Target: EGFR
AZD5363
Target: AKT
AZD8931
Target: HER2, EGFR
Selumetinib
Target: MEK
Vandetanib
Target: VEGF, EGFR
Bicalutamide
target: Androgen receptor
Olaparib
Target: PARP
Anthracyclines
DNA intercalation
Taxanes
Target: mitotic tubulin and microtubules
cyclophosphamide
Alkylating agents
DNA intercalators
DNA intercalators
Methotrexate
DNA intercalators
vinca alkaloids
Target: mitotic tubulin and microtubules
Platinum based chemotherapies
Platinum based chemotherapies
Bevacizumab
Target: VEGF
Mitomycin C
Alkylating agents
Eribulin
Microtubule modulator
MEDI4736
Target: PD-L1
Centre Georges François Leclerc, Dijon
Polyclinique Bordeaux Nord Aquitaine, Bordeaux
Hopitaux Du Leman, Thonon-les-Bains
Chd Vendee, La Roche-sur-Yon
Chu Dupuytren, Limoges
Institut de Cancérologie de l'Ouest/Paul Papin, Angers
Institut Sainte-Catherine, Avignon
Institut Bergonié, Bordeaux
Centre François Baclesse, Caen
Centre Jean Perrin, Clermont-Ferrand
Centre Oscar Lambret, Lille
Centre Hospitalier Lyon Sud, Lyon
Centre Léon Bérard, Lyon
Institut Paoli Calmettes, Marseille
Institut Régional du Cancer Montpellier Val d'Aurelle, Montpellier
Centre Alexis Vautrin, Nancy
Institut de Cancérologie de l'Ouest/ René Gauducheau, Nantes
Centre Antoine Lacassagne, Nice
Institut Curie, Paris
Centre Eugène Marquis, Rennes
Centre Henri Becquerel, Rouen
Institut Curie, Saint-Cloud
Hopitaux Universitaire de Strasbourg - Hopital Civil, Strasbourg
Institut Claudius Regaud, Toulouse
Gustave Roussy, Villejuif
Collaborators (1)
Fondation ARC
OTHER
AstraZeneca
INDUSTRY
UNICANCER
OTHER